Moderna expects approximately $4 billion in cash costs in 2027
MRNA•Moderna expects annual cash costs of about $4 billion to $4.5 billion from 2027 through 2030 and anticipates ending 2026 with about $9 billion in total liquidity. It also extended the maturity of its $1.5 billion Ares credit facility to 2031.
1. Costs and liquidity
Moderna expects annual cash costs of about $4 billion to $4.5 billion from 2027 through 2030. The company anticipates ending 2026 with about $9 billion in total liquidity, including cash, investments and undrawn borrowing capacity.
2. Credit facility and launch
Moderna extended the maturity of its $1.5 billion Ares credit facility to 2031. Following U.S. and Canadian approvals of Mflusiva in 2026, the company is preparing for a broader commercial launch during the 2027-2028 respiratory season.
